Get the Stockscreener App
0.00
100.00%
-104.91
Exact Sciences Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$104.91
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$20.03B
Revenue:
$3.25B
Net Income/Loss:
$-207.95M
P/E Ratio:
0.00
EPS:
-1.1046
Net Cash Flow:
$356.78M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$104.98
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
0.00 | 20.03B | 3.25B | -207.95M | 356.78M | -1.1046 |
TMO
Thermo Fisher Scientific Inc
|
492.51 | 181.06B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
182.67 | 127.84B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.53 | 44.81B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.53 | 38.21B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
383.57 | 36.00B | 3.77B | 449.25M | 240.68M | 7.8556 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Mizuho | Outperform → Neutral |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Exact Sciences Corp stock (US30063P1057): Nasdaq-listed cancer diagnostics group steady after recent - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Abbott buyout clouds listing status and sector role - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Abbott deal reshapes outlook for cancer diagnostics leade - AD HOC NEWS
Canaccord Genuity Downgrades Exact Sciences (EXAS) - MSN
Exact Sciences stock (US30063P1057): Diagnostics peer update after Petrichor hiring - AD HOC NEWS
Exact Sciences stock (US30063P1057): screening business, oncology focus, and what U.S. investors are - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): diagnostics specialist in focus after leadership news - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): earnings backdrop and cancer diagnostics focus - AD HOC NEWS
Exact Sciences Corp stock (US30063P1057): acquisition plans stir debate around growth and dilution - AD HOC NEWS
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know - TradingKey
Exact Sciences stock (US30063P1057): latest business update and investor focus - AD HOC NEWS
TD Cowen Maintains Exact Sciences (EXAS) Buy Recommendation - MSN
Exact Sciences stock (US30063P1057): Screening leader faces a new investor test - AD HOC NEWS
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Exact Sciences Corp. stock (US30063P1057): earnings beat and Abbott takeover reshape cancer diagnost - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B - AD HOC NEWS
Exact Sciences stock (US30063P1057): Q1 2026 revenue growth driven by Cologuard and Oncotype DX - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Risk channels signal institutional focus - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Q1 2026 earnings and screening advancements - AD HOC NEWS
BTIG Downgrades Exact Sciences (EXAS) - MSN
Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue up 23% - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue growth - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Q4 2025 earnings miss on EPS despite revenue beat - AD HOC NEWS
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - MSN
Exact Sciences Corp. Stock (US30063P1057): Q1 2026 Earnings Release Scheduled for May 7 - AD HOC NEWS
Kevin Conroy (ABBOTT LABORATORIES: ABT) reports 131,451-share Form 3 holding - Stock Titan
Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Exact Sciences Acquisition - Quiver Quantitative
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits - MSN
Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account - Investing.com India
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock - AD HOC NEWS
Abbott Laboratories Slammed On Its Post-Exact Sciences Guidance - Investor's Business Daily
Abbott trims 2026 profit forecast on Exact deal hit, shares fall - Reuters
Q1 progress positions Abbott for accelerating growth in 2026 - Abbott
Abbott Cuts Profit Forecast After $21 Billion Deal, Shares Fall 4.6% - TradingView
Abbott cuts profit forecast in wake of Exact Sciences deal - Modern Healthcare
Abbott cuts 2026 profit forecast on Exact deal, shares fall - BioWorld News
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag - Yahoo! Finance Canada
Earnings call transcript: Abbott Labs Q1 2026 results align with expectations - Investing.com
Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know - TradingKey
Abbott reports Q1 earnings, completes Exact Sciences acquisition - Investing.com
Abbott lowers earnings forecast after $21B Exact Sciences buy - Yahoo Finance
Abbott results beat on medical device boost, Exact deal hits forecast - Yahoo Finance
Abbott (ABT) Q1 2026 earnings rise on adjusted basis after Exact Sciences acquisition - Stock Titan
Abbott adds Exact Sciences, expands into fast-growing cancer tests - Stock Titan
Abbott’s Exact acquisition drives med-tech M&A to $23.7B in March - BioWorld News
Abbott Verdict And Exact Sciences Deal Reshape Risk And Growth Outlook - Yahoo Finance
Exact Sciences to Participate in June Investor Conferences - Yahoo
Abbott’s $23 billion Exact Sciences deal revives diagnostics growth ambitions - S&P Global
Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus - AD HOC NEWS
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):